Cramer's 'Mad Money' Recap: Europe's Problems Difficult but Can Be Solved

NXP Semiconductors (NXPI): "This market is too tough. I don't want you to buy any semiconductors right now. See you in September."

Clean Energy Fuels (CLNE): "This is completely speculative. You're betting on companies switching to natural gas. They haven't done it yet, so until then you're stuck."

VIVUS (VVUS): "I like it as a speculation. I think it's a good one."

Carter's (CRI): "Keep looking, don't touch. They have no growth. I don't want to touch any no-growth situations."

Executive Decision

In the "Executive Decision" segment, Cramer sat down with Clay Siegall, president and CEO of Seattle Genetics (SGEN), another cancer-fighting company presenting at the American Society of Clinical Oncology conference this week.

Siegall explained that Seattle Genetics' cancer drugs use target antibodies to dock with tumor cells and kill them while leaving surrounding, healthy cells untouched. He said the result is a less toxic, targeted therapy. Seattle Genetics is currently developing seven such treatments to attack both solid and liquid tumors.

Another part of Seattle Genetics' strategy is to utilize local community doctors, rather than large hospitals, to administer their treatments. He said the 30-minute infusions are easy to administer and patients much prefer to be seen by their regular doctors.

When asked about the potential of their treatments, Siegall said his company has 10 to 15 different trials in the pipeline and he's confident the treatments will be successful in treating different types of cancers as well.

With the frontline treatment for cancer having changed little since its introduction in 1977, Cramer said companies like Seattle Genetics are offering hope for newer, safer and more effective cancer treatments, which is why he remains bullish on the company.

No Huddle Offense

In his "No Huddle Offense" segment, Cramer looked at the shares of Caterpillar (CAT), an industrial stock in the crosshairs of a potential global recession, to ask, "What's a fair valuation for this earth-moving equipment powerhouse?"

Cramer said Caterpillar shares have already fallen 30% from their high of $116. However, during the recession of 2008 and 2009, a time when earnings fell by 60%, shares of Caterpillar fell a whopping 75%. Could investors be in for a similar decline now to $36 a share?

« First ‹ Previous 1 2 3 4 Next › Last »